AMWL Fundamental Analysis - AMERICAN WELL CORP-CLASS A

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to AMWL. AMWL was compared to 35 industry peers in the Health Care Technology industry. While AMWL has a great health rating, there are worries on its profitability. While showing a medium growth rate, AMWL is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year AMWL has reported negative net income.

AMWL had a negative operating cash flow in the past year.

AMWL had negative earnings in each of the past 5 years.

AMWL had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

AMWL has a Return On Assets of -31.56%. This is in the lower half of the industry: AMWL underperforms 65.71% of its industry peers.

AMWL has a Return On Equity (-44.50%) which is in line with its industry peers.

		Industry Rank	Sector Rank
ROA	-31.56%
ROE	-44.5%
ROIC	N/A

ROA(3y)-61.48%

ROA(5y)-42.59%

ROE(3y)-79.72%

ROE(5y)-54.34%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a Gross Margin value of 52.93%, AMWL is not doing good in the industry: 65.71% of the companies in the same industry are doing better.

In the last couple of years the Gross Margin of AMWL has declined.

The Profit Margin and Operating Margin are not available for AMWL so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	52.93%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.79%

GM growth 5Y-3.32%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AMWL does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for AMWL has been reduced compared to 1 year ago.

Compared to 5 years ago, AMWL has less shares outstanding

There is no outstanding debt for AMWL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

AMWL has an Altman-Z score of -7.16. This is a bad value and indicates that AMWL is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -7.16, AMWL is not doing good in the industry: 82.86% of the companies in the same industry are doing better.

There is no outstanding debt for AMWL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-7.16

ROIC/WACCN/A

WACC9.83%

2.3 Liquidity

AMWL has a Current Ratio of 3.14. This indicates that AMWL is financially healthy and has no problem in meeting its short term obligations.

With a decent Current ratio value of 3.14, AMWL is doing good in the industry, outperforming 68.57% of the companies in the same industry.

AMWL has a Quick Ratio of 3.11. This indicates that AMWL is financially healthy and has no problem in meeting its short term obligations.

With a decent Quick ratio value of 3.11, AMWL is doing good in the industry, outperforming 68.57% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.14
Quick Ratio	3.11

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

AMWL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.07%, which is quite impressive.

The Revenue has been growing slightly by 4.33% in the past year.

The Revenue has been growing by 11.30% on average over the past years. This is quite good.

EPS 1Y (TTM)46.07%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%30.31%

Revenue 1Y (TTM)4.33%

Revenue growth 3Y0.21%

Revenue growth 5Y11.3%

Sales Q2Q%-7.8%

3.2 Future

AMWL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.97% yearly.

AMWL is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.88% yearly.

EPS Next Y55.07%

EPS Next 2Y28.88%

EPS Next 3Y20.77%

EPS Next 5Y12.97%

Revenue Next Year-1.28%

Revenue Next 2Y-1.91%

Revenue Next 3Y0.66%

Revenue Next 5Y0.88%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

AMWL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year AMWL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as AMWL's earnings are expected to grow with 20.77% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y28.88%

EPS Next 3Y20.77%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for AMWL!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

AMERICAN WELL CORP-CLASS A

NYSE:AMWL (12/29/2025, 4:15:00 PM)

4.58

+0.03 (+0.66%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Technology

Earnings (Last)11-04 2025-11-04/amc

Earnings (Next)02-10 2026-02-10/amc

Inst Owners40.07%

Inst Owner Change0%

Ins Owners4.11%

Ins Owner Change0.25%

Market Cap74.97M

Revenue(TTM)265.02M

Net Income(TTM)-113.43M

Analysts70.67

Price Target8.33 (81.88%)

Short Float %1.13%

Short Ratio1.27

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)10.58%

Min EPS beat(2)-9.03%

Max EPS beat(2)30.19%

EPS beat(4)3

Avg EPS beat(4)14.89%

Min EPS beat(4)-9.03%

Max EPS beat(4)31.2%

EPS beat(8)6

Avg EPS beat(8)10.08%

EPS beat(12)7

Avg EPS beat(12)-7.18%

EPS beat(16)10

Avg EPS beat(16)-3.2%

Revenue beat(2)2

Avg Revenue beat(2)4.89%

Min Revenue beat(2)1.14%

Max Revenue beat(2)8.64%

Revenue beat(4)4

Avg Revenue beat(4)5.82%

Min Revenue beat(4)1.14%

Max Revenue beat(4)8.93%

Revenue beat(8)4

Avg Revenue beat(8)1.61%

Revenue beat(12)4

Avg Revenue beat(12)-0.13%

Revenue beat(16)5

Avg Revenue beat(16)-0.19%

PT rev (1m)-6.28%

PT rev (3m)-17.15%

EPS NQ rev (1m)3.37%

EPS NQ rev (3m)5.21%

EPS NY rev (1m)-0.37%

EPS NY rev (3m)-0.37%

Revenue NQ rev (1m)-0.92%

Revenue NQ rev (3m)-5.09%

Revenue NY rev (1m)-0.44%

Revenue NY rev (3m)-0.44%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.28
P/FCF	N/A
P/OCF	N/A
P/B	0.29
P/tB	0.42
EV/EBITDA	N/A

EPS(TTM)-7.89

EYN/A

EPS(NY)-4.75

Fwd EYN/A

FCF(TTM)-3.94

FCFYN/A

OCF(TTM)-3.79

OCFYN/A

SpS16.19

BVpS15.57

TBVpS11.02

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-31.56%
ROE	-44.5%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	52.93%
FCFM	N/A

ROA(3y)-61.48%

ROA(5y)-42.59%

ROE(3y)-79.72%

ROE(5y)-54.34%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.79%

GM growth 5Y-3.32%

F-Score6

Asset Turnover0.74

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	7.2%
Cap/Sales	0.92%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.14
Quick Ratio	3.11
Altman-Z	-7.16

F-Score6

WACC9.83%

ROIC/WACCN/A

Cap/Depr(3y)44.83%

Cap/Depr(5y)34.13%

Cap/Sales(3y)5.21%

Cap/Sales(5y)3.44%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)46.07%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%30.31%

EPS Next Y55.07%

EPS Next 2Y28.88%

EPS Next 3Y20.77%

EPS Next 5Y12.97%

Revenue 1Y (TTM)4.33%

Revenue growth 3Y0.21%

Revenue growth 5Y11.3%

Sales Q2Q%-7.8%

Revenue Next Year-1.28%

Revenue Next 2Y-1.91%

Revenue Next 3Y0.66%

Revenue Next 5Y0.88%

EBIT growth 1Y52.11%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year79.78%

EBIT Next 3Y25.56%

EBIT Next 5Y15.16%

FCF growth 1Y61.42%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y56.53%

OCF growth 3YN/A

OCF growth 5YN/A

AMERICAN WELL CORP-CLASS A / AMWL FAQ

Can you provide the ChartMill fundamental rating for AMERICAN WELL CORP-CLASS A?

ChartMill assigns a fundamental rating of 3 / 10 to AMWL.

What is the valuation status for AMWL stock?

ChartMill assigns a valuation rating of 1 / 10 to AMERICAN WELL CORP-CLASS A (AMWL). This can be considered as Overvalued.

Can you provide the profitability details for AMERICAN WELL CORP-CLASS A?

AMERICAN WELL CORP-CLASS A (AMWL) has a profitability rating of 0 / 10.

What is the financial health of AMERICAN WELL CORP-CLASS A (AMWL) stock?

The financial health rating of AMERICAN WELL CORP-CLASS A (AMWL) is 7 / 10.

AMERICAN WELL CORP-CLASS A (AMWL) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

AMERICAN WELL CORP-CLASS A / AMWL FAQ

Can you provide the ChartMill fundamental rating for AMERICAN WELL CORP-CLASS A?

What is the valuation status for AMWL stock?

Can you provide the profitability details for AMERICAN WELL CORP-CLASS A?

What is the financial health of AMERICAN WELL CORP-CLASS A (AMWL) stock?